🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Hirva Mamdani presenting DDR gene associations with TMB from Caris Life Sciences Rebecca Feldman, PhD

ascopubs.org/doi/full/10.12… Hot off the press, Our paper on resuming ICI after colitis in JCO. Big multicenter effort led my Mimi wang from MD Anderson Cancer Center Journal of Clinical Oncology Society for Immunotherapy of Cancer @gulleyj1 Elad Sharon. 34 %recurrence, more with anti ctla4 than antipd1.

It's time for CASPIAN results. Wonderfully delivered by Dr. Luis Paz-Ares, the study shows that durvalumab + cisplatin- or carboplatin-etoposide in ES-SCLC provides an important new treatment option for patients and physicians. #LCSM #SCLC #WCLC19

I am thrilled that in 1 week we had approvals of selpercatinib for RET altered NSCLC and capmatinib for METexon14skip NSCLC. So important to test all NSCLC pts for all actionable mutations so we can provide the best treatment options.

#ASCO20 Analysis of the VA database comparing cisplatin vs carboplatin in #SCLC shows no difference in OS (even in subset of patients who were younger and PS 0) - Hirva Mamdani #OncoAlert #LCSM

#ASCO21 Using Caris Life Sciences in #NSCLC we 💡 -> Diff in tumor immune microenv and glutamine metab in STK11 mut vs. STK11/ TP53 comut Used OAK/POPLAR data to see outcomes. -> These unique vulnerabilities in STK11 NSCLC could be important Stephen V Liu, MD Chul Kim Hossein Borghaei, DO

#ASCO21 Dr. Oladimeji Akinboro with FDA Oncology presents a pooled analysis of chemo/IO vs IO alone for 1L treatment of PDL1 low (1-49%) NSCLC. With lack of head to head trials in this subset, this is a useful dataset. #LCSM OncoAlert Harpreet Singh, MD

What is the best platinum agent sensitizer in limited-stage SCLC? Presenting new data from VA #ASCO21 #LCSM #SCLC

Kicking off #TTLC23 with keynote address by Lauren Averett Byers, MD. Thrilled to attend the meeting in person!

Excited to be @iaslc #ttlc23! Lauren Averett Byers, MD is kicking off the meeting with a fantastic keynote on SCLC! She is highlighting the great promises ahead with a focus on biomarker driven options. #lcsm

Marching ahead in battle against small cell lung cancer. 226 clinical trials (active/pending activation) in 2023! ‘From a bleak past to promising future’ - Lauren Averett Byers, MD. Inspiring keynote address at #TTLC23!

Fantastic SCLC panel #TTLC23 One clear theme of this meeting is that major advances in SCLC are coming soon and hopefully this dz will be labeled “recalcitrant” no more Lauren Averett Byers, MD @cbmeador Dr Jalal Taofeek K Owonikoko Ticiana Batista (Leal) Anne Chiang Triparna Sen (Sen-Lab) Dr. Nagla Abdel Karim Wade Iams

Inspiring session at #TTLC23: Women in thoracic oncology. Mentorship/sponsorship continuum - Amplify, Boost, Connect, Defend. Charu Aggarwal, MD, MPH, FASCO Lecia Sequist, MD, MPH

What a beautiful celebration of legendary Corey Langer’s amazing career- spent way beyond the median and keeps going! We all “endorse”😉 his poem’s beautiful message! #lcsm IASLC

Happy to finally share our analysis examining the role of surgery in stage I SCLC at the VA Veterans Affairs Clinical Lung Cancer Hirva Mamdani Omid Yazdanpanah Samer Alkassis, MD Vik Dhillon sciencedirect.com/science/articl… 🧵below

Great presentation and discussion of KEYNOTE 671 by Heather Wakelee and Mark Awad at #ASCO23 Another evidence in support of neoadjuvant Chemo-IO for patients with resectable NSCLC (stage II-IIIb AJCC 8). EFS curves suggest possible contribution of adjuvant IO to long term outcomes

Neoadjuvant +/- adjuvant therapy for resectable NSCLC. Need more personalized approaches to guide decisions on de-escalation and perhaps escalation of therapy to cure more patients and avoid overtreatment. Lung cancer screening is critical to diagnose early stage disease. #ASCO23

We are so proud of our fellow Richa Parikh for presenting a poster on diet and risk of multiple myeloma at #ASCO23 👏🏽👏🏽👏🏽 meetings.asco.org/abstracts-pres…

Our Caris Life Sciences POA poster about KRAS KEAP and STK11, the largest study done in these genetic aberratios showing bad prognosis with IO Stephen V Liu, MD @DrSteveMartin Dr. Nagla Abdel Karim Hossein Borghaei, DO Hina Khan Hirva Mamdani #LCSM

Karmanos Lung Cancer Symposium: Taofeek K Owonikoko Greg Durm @MeeraRPatel Sonam Puri MD, Antoinette Wozniak. Thought provoking discussion on latest advances in lung cancer treatment. This is arguably the most exciting time to be a thoracic oncologist! Karmanos Cancer Institute #lcam